Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Completed · Not applicable

Conditions studied: HIV Infections

In brief

To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.

Key facts

Study ID: NCT00002029
Run by: Abbott
Last updated by the study team: 2009-02-20

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Concurrent Medication:
Allowed:
Zidovudine (AZT).
All drugs used for the standard treatment of opportunistic infections.
Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.
Patients must have:
Diagnosis of AIDS.
Weight loss of > 10 percent premorbid body weight.
Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.
Require home total parenteral nutrition (TPN) for a period of approximately 3 months.
Life expectancy = or > 90 days.
Prior Medication:
Allowed:
Zidovudine (AZT).

You may not qualify if…

Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Life expectancy < 90 days.
Biliary stasis.
History of drug abuse.
Patients with the following are excluded:
Life expectancy < 90 days.
Biliary stasis.
History of drug abuse.
Prior Medication:
Excluded within 3 months of study entry:
Immunomodulators.
Experimental antiviral DT. History of drug abuse.

Where it is running

Intracare Inc — Miami, Florida, United States
East Orange Veterans Administration Med Ctr — East Orange, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.